for subcutaneous use Initial U.S. Approval: 2017
Facts about guselkumab injection
MEDICINE APPROVED BY-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Pharmaceuticals and Medical Devices Agency (PMDA), Therapeutic Goods Administration (TGA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “guselkumab injection” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For guselkumab injection
Approved accessible "guselkumab injection"
Guselkumab, sold under the brand name Tremfya, is a monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis. Guselkumab is indicated to treat moderate to severe plaque psoriasis, and psoriatic arthritis in adults. Guselkumab is provided as a subcutaneous injection of 100 mg given every eight weeks (except for the second dose, which is given four weeks after the first dose)
How can 1 go about obtaining guselkumab injection?
If guselkumab injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
TREMFYA (guselkumab) injection, for subcutaneous use Initial U.S. Approval: 2017
- Summary of Product Characteristics [FDA]: Tremfya (guselkumab) [PDF] Janssen, July 2017
- Janssen Announces US FDA Approval of TREMFYA™ (guselkumab) For The Treatment Of Moderate To Severe Plaque Psoriasis Janssen press release, July 13, 2017
- Tremfya (guselkumab) European Medicines Agency (EMA) information, last checked on Sept 2, 2020
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa